Pharmacogenetics and Analgesic Effects of Antidepressants in Chronic Pain Management

References

• Cruccu G , SommerC , AnandPet al. EFNS guidelines on neuropathic pain assessment: revised 2009 . Eur. J. Neurol.17 ( 8 ), 1010 – 1018 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dworkin RH , O’ConnorAB , AudetteJet al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update . Mayo Clin. Proc.85 ( 3 Suppl. ), S3 – S14 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Fishbain DA , CutlerR , RosomoffHL , RosomoffRS . Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review . Pain Med.1 ( 4 ), 310 – 316 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Fishbain D . Evidence-based data on pain relief with antidepressants . Ann. Med.32 ( 5 ), 305 – 316 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Breivik H , CollettB , VentafriddaV , CohenR , GallacherD . Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment . Eur. J. Pain10 ( 4 ), 287 – 333 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Elliott AM , SmithBH , PennyKI , SmithWC , ChambersWA . The epidemiology of chronic pain in the community . Lancet354 ( 9186 ), 1248 – 1252 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Tyrer S . Psychiatric assessment of chronic pain . Br. J. Psychiatry160 , 733 – 741 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Magni G . On the relationship between chronic pain and depression when there is no organic lesion . Pain31 ( 1 ), 1 – 21 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Manchikanti L , PampatiV , BeyerC , DamronK , BarnhillRC . Evaluation of psychological status in chronic low back pain: comparison with general population . Pain Physician5 ( 2 ), 149 – 155 ( 2002 ).
   PubMedGoogle Scholar
• Wernicke JF , PritchettYL , D’souzaDNet al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain . Neurology67 ( 8 ), 1411 – 1420 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rigal F , EschalierA , DevoizeJL , PechadreJC . Activities of five antidepressants in a behavioral pain test in rats . Life Sci.32 ( 26 ), 2965 – 2971 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Coquoz D , PorchetHC , DayerP . Central analgesic effects of antidepressant drugs with various mechanisms of action: desipramine, fluvoxamine and moclobemide . Schweiz. Med. Wochenschr.121 ( 49 ), 1843 – 1845 ( 1991 ).
   PubMedGoogle Scholar
• Onghena P , Van HoudenhoveB . Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies . Pain49 ( 2 ), 205 – 219 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Pertovaara A . Noradrenergic pain modulation . Prog. Neurobiol.80 ( 2 ), 53 – 83 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mico JA , ArdidD , BerrocosoE , EschalierA . Antidepressants and pain . Trends Pharmacol. Sci.27 ( 7 ), 348 – 354 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Moore DJ , KeoghE , EcclestonC . The effect of threat on attentional interruption by pain . Pain154 ( 1 ), 82 – 88 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kvinesdal B , MolinJ , FrolandA , GramLF . Imipramine treatment of painful diabetic neuropathy . JAMA251 ( 13 ), 1727 – 1730 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Rasmussen PV , JensenTS , SindrupSH , BachFW . TDM-based imipramine treatment in neuropathic pain . Ther. Drug Monit.26 ( 4 ), 352 – 360 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Max MB , LynchSA , MuirJ , ShoafSE , SmollerB , DubnerR . Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy . N. Engl. J. Med.326 ( 19 ), 1250 – 1256 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Hammack JE , MichalakJC , LoprinziCLet al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy . Pain98 ( 1–2 ), 195 – 203 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Verdu B , DecosterdI , BuclinT , StiefelF , BerneyA . Antidepressants for the treatment of chronic pain . Drugs68 ( 18 ), 2611 – 2632 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Raskin J , WangF , PritchettYL , GoldsteinDJ . Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study . Pain Med.7 ( 5 ), 373 – 385 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study . Pain110 ( 3 ), 697 – 706 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Semenchuk MR , ShermanS , DavisB . Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain . Neurology57 ( 9 ), 1583 – 1588 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Li TC , ShiahIS , SunCJ , TzangRF , HuangKC , LeeWK . Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature . J. ECT27 ( 2 ), 165 – 167 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brau ME , DreimannM , OlschewskiA , VogelW , HempelmannG . Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na(+) currents in rat sensory neurons . Anesthesiology94 ( 1 ), 137 – 144 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Sindrup SH , OttoM , FinnerupNB , JensenTS . Antidepressants in the treatment of neuropathic pain . Basic Clin. Pharmacol. Toxicol.96 ( 6 ), 399 – 409 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wang GK , RussellC , WangSY . State-dependent block of voltage-gated Na +channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain . Pain110 ( 1–2 ), 166 – 174 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Pancrazio JJ , KamatchiGL , RoscoeAK , LynchC3rd . Inhibition of neuronal Na+ channels by antidepressant drugs . J. Pharmacol. Exp. Ther.284 ( 1 ), 208 – 214 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Markowitz JS , PatrickKS . Venlafaxine-tramadol similarities . Med. Hypotheses51 ( 2 ), 167 – 168 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Saarto T , WiffenPJ . Antidepressants for neuropathic pain: a Cochrane review . J. Neurol. Neurosurg. Psychiatry81 ( 12 ), 1372 – 1373 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sindrup SH , BjerreU , DejgaardA , BrosenK , Aaes-JorgensenT , GramLF . The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy . Clin. Pharmacol. Ther.52 ( 5 ), 547 – 552 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Timmerman L , StellemaR , StronksDL , GroenewegG , HuygenFJ . Adherence to pharmacological pain therapy in patients with nonmalignant pain: the role of patients’ knowledge of pain medication . Pain Pract.14 ( 8 ), 701 – 708 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Broekmans S , DobbelsF , MilisenK , MorlionB , VanderschuerenS . Medication adherence in patients with chronic non-malignant pain: is there a problem?Eur. J. Pain13 ( 2 ), 115 – 123 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Able SL , CuiZ , ShenW . Duloxetine treatment adherence across mental health and chronic pain conditions . Clinicoecon. Outcomes Res.6 , 75 – 81 ( 2014 ).
   PubMedGoogle Scholar
• Franceschi M , ScarcelliC , NiroVet al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients . Drug Saf.31 ( 6 ), 545 – 556 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rush AJ , TrivediMH , WisniewskiSRet al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report . Am. J. Psychiatry163 ( 11 ), 1905 – 1917 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Laje G , McmahonFJ . Genome-wide association studies of antidepressant outcome: a brief review . Prog. Neuropsychopharmacol. Biol. Psychiatry35 ( 7 ), 1553 – 1557 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Garriock HA , KraftJB , ShynSIet al. A genomewide association study of citalopram response in major depressive disorder . Biol. Psychiatry67 ( 2 ), 133 – 138 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Aberg K , AdkinsDE , LiuYet al. Genome-wide association study of antipsychotic-induced QTc interval prolongation . Pharmacogenomics J.12 ( 2 ), 165 – 172 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kato M , FukudaT , SerrettiAet al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder . Prog. Neuropsychopharmacol. Biol. Psychiatry32 ( 2 ), 398 – 404 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Arias B , CatalanR , GastoC , GutierrezB , FananasL . Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram . J. Psychopharmacol.19 ( 2 ), 166 – 172 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Arias B , SerrettiA , LorenziC , GastoC , CatalanR , FananasL . Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin . J. Affect. Disord.90 ( 2–3 ), 251 – 256 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kawanishi C , LundgrenS , AgrenH , BertilssonL . Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study . Eur. J. Clin. Pharmacol.59 ( 11 ), 803 – 807 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Bertilsson L , DahlML , DalenP , Al-ShurbajiA . Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs . Br. J. Clin. Pharmacol.53 ( 2 ), 111 – 122 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Spina E , GittoC , AvenosoA , CampoGM , CaputiAP , PeruccaE . Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study . Eur. J. Clin. Pharmacol.51 ( 5 ), 395 – 398 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Steimer W , ZopfK , Von AmelunxenSet al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy . Clin. Chem.51 ( 2 ), 376 – 385 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Lessard E , YessineMA , HamelinBA , O’HaraG , LeblancJ , TurgeonJ . Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans . Pharmacogenetics9 ( 4 ), 435 – 443 ( 1999 ).
   PubMedGoogle Scholar
• Uhr M , TontschA , NamendorfCet al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression . Neuron57 ( 2 ), 203 – 209 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Peters EJ , SlagerSL , KraftJBet al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample . PLoS ONE3 ( 4 ), e1872 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Serretti A , KatoM , De RonchiD , KinoshitaT . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients . Mol. Psychiatry12 ( 3 ), 247 – 257 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Serretti A , GibiinoS , OlgiatiP . Pharmacogenetics of antidepressants and mood stabilizers . Handb. Clin. Neurol.106 , 715 – 744 ( 2012 ).
   PubMedGoogle Scholar
• Weizman S , GondaX , DomeP , FaludiG . Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder . Neuropsychopharmacol. Hung.14 ( 2 ), 87 – 101 ( 2012 ).
   PubMedGoogle Scholar
• Schosser A , KasperS . The role of pharmacogenetics in the treatment of depression and anxiety disorders . Int. Clin. Psychopharmacol.24 ( 6 ), 277 – 288 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Crisafulli C , FabbriC , PorcelliSet al. Pharmacogenetics of antidepressants . Front. Pharmacol.2 , 6 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Porcelli S , DragoA , FabbriC , GibiinoS , CalatiR , SerrettiA . Pharmacogenetics of antidepressant response . J. Psychiatry Neurosci.36 ( 2 ), 87 – 113 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Porcelli S , FabbriC , SerrettiA . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy . Eur. Neuropsychopharmacol.22 ( 4 ), 239 – 258 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Binder EB , HolsboerF . Pharmacogenomics and antidepressant drugs . Ann. Med.38 ( 2 ), 82 – 94 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Zobel A , MaierW . Pharmacogenetics of antidepressive treatment . Eur. Arch. Psychiatry Clin. Neurosci.260 ( 5 ), 407 – 417 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Horstmann S , BinderEB . Pharmacogenomics of antidepressant drugs . Pharmacol Ther124 ( 1 ), 57 – 73 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kato M , SerrettiA . Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder . Mol. Psychiatry15 ( 5 ), 473 – 500 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kapur BM , LalaPK , ShawJL . Pharmacogenetics of chronic pain management . Clin. Biochem.47 ( 13–14 ), 1169 – 1187 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rollason V , SamerC , PiguetV , DayerP , DesmeulesJ . Pharmacogenetics of analgesics: toward the individualization of prescription . Pharmacogenomics9 ( 7 ), 905 – 933 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rollason V , SamerCF , DaaliY , DesmeulesJA . Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review . Curr. Drug Metab.15 ( 3 ), 326 – 343 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wyatt JE , PettitWL , HarirforooshS . Pharmacogenetics of nonsteroidal anti-inflammatory drugs . Pharmacogenomics J.12 ( 6 ), 462 – 467 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Smith MT , MuralidharanA . Pharmacogenetics of pain and analgesia . Clin. Genet.82 ( 4 ), 321 – 330 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Singh AB , BousmanCA , NgC , BerkM . Antidepressant pharmacogenetics . Curr. Opin. Psychiatry27 ( 1 ), 43 – 51 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fabbri C , Di GirolamoG , SerrettiA . Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research . Am. J. Med. Genet. B Neuropsychiatr. Genet.162B ( 6 ), 487 – 520 ( 2013 ).
   PubMedGoogle Scholar
• Niitsu T , FabbriC , BentiniF , SerrettiA . Pharmacogenetics in major depression: a comprehensive meta-analysis . Prog. Neuropsychopharmacol. Biol. Psychiatry45 , 183 – 194 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SwenJJ , ThornCFet al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clin. Pharmacol. Ther.93 ( 5 ), 402 – 408 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Narasimhan S , LohoffFW . Pharmacogenetics of antidepressant drugs: current clinical practice and future directions . Pharmacogenomics13 ( 4 ), 441 – 464 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Murphy E , McMahonFJ . Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations . Discov. Med.16 ( 87 ), 113 – 122 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Murphy E , HouL , MaherBSet al. Race, genetic ancestry and response to antidepressant treatment for major depression . Neuropsychopharmacology38 ( 13 ), 2598 – 2606 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Leijon G , BoivieJ . Central post-stroke pain–a controlled trial of amitriptyline and carbamazepine . Pain36 ( 1 ), 27 – 36 ( 1989 ).
   PubMed Web of Science ®Google Scholar
• Sindrup SH , GramLF , SkjoldT , FrolandA , Beck-NielsenH . Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms . Clin. Pharmacol. Ther.47 ( 4 ), 509 – 515 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Staddon S , ArranzMJ , MancamaD , MataI , KerwinRW . Clinical applications of pharmacogenetics in psychiatry . Psychopharmacology (Berl.)162 ( 1 ), 18 – 23 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Zanger UM , RaimundoS , EichelbaumM . Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry . Naunyn Schmiedebergs Arch. Pharmacol.369 ( 1 ), 23 – 37 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Samer CF , LorenziniKI , RollasonV , DaaliY , DesmeulesJA . Applications of CYP450 testing in the clinical setting . Mol. Diagn. Ther.17 ( 3 ), 165 – 184 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , SimSC , GomezA , Rodriguez-AntonaC . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects . Pharmacol. Ther.116 ( 3 ), 496 – 526 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mcgraw J , WallerD . Cytochrome P450 variations in different ethnic populations . Expert Opin. Drug Metab. Toxicol.8 ( 3 ), 371 – 382 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants . Pharmacogenomics3 ( 2 ), 229 – 243 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chen S , ChouWH , BlouinRAet al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry . Clin. Pharmacol. Ther.60 ( 5 ), 522 – 534 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Cascorbi I . Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication . Eur. J. Clin. Invest.33 ( Suppl. 2 ), 17 – 22 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Tsai MH , LinKM , HsiaoMCet al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response . Pharmacogenomics11 ( 4 ), 537 – 546 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lobello KW , PreskornSH , Guico-PabiaCJet al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder . J. Clin. Psychiatry71 ( 11 ), 1482 – 1487 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sindrup JH , PetersenLJ , KastrupJ , WroblewskiH , KristensenJK . Lack of effect of peripheral nervous blockade on nocturnal fluctuations in lower-leg subcutaneous blood flow in man . Clin. Sci. (Lond.)84 ( 3 ), 297 – 304 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Zahari Z , IsmailR . Influence of cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics . Drug Metab. Pharmacokinet.29 ( 1 ), 29 – 43 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith G , StubbinsMJ , HarriesLW , WolfCR . Molecular genetics of the human cytochrome P450 monooxygenase superfamily . Xenobiotica28 ( 12 ), 1129 – 1165 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Rudberg I , MohebiB , HermannM , RefsumH , MoldenE . Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients . Clin. Pharmacol. Ther.83 ( 2 ), 322 – 327 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Yin OQ , WingYK , CheungYet al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients . J. Clin. Psychopharmacol.26 ( 4 ), 367 – 372 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Welfare MR , AitkinM , BassendineMF , DalyAK . Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians . Pharmacogenetics9 ( 3 ), 367 – 375 ( 1999 ).
   PubMedGoogle Scholar
• Fuhr U , RostKL . Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva . Pharmacogenetics4 ( 3 ), 109 – 116 ( 1994 ).
   PubMedGoogle Scholar
• Tantcheva-Poor I , ZaiglerM , RietbrockS , FuhrU . Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test . Pharmacogenetics9 ( 2 ), 131 – 144 ( 1999 ).
   PubMedGoogle Scholar
• Sachse C , BrockmollerJ , BauerS , RootsI . Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine . Br. J. Clin. Pharmacol.47 ( 4 ), 445 – 449 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Knadler MP , LoboE , ChappellJ , BergstromR . Duloxetine: clinical pharmacokinetics and drug interactions . Clin. Pharmacokinet.50 ( 5 ), 281 – 294 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Li J , MenardV , BenishRLet al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment . Pharmacogenomics13 ( 5 ), 555 – 570 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lerman C , ShieldsPG , WileytoEPet al. Pharmacogenetic investigation of smoking cessation treatment . Pharmacogenetics12 ( 8 ), 627 – 634 ( 2002 ).
   PubMedGoogle Scholar
• Hesse LM , HeP , KrishnaswamySet al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes . Pharmacogenetics14 ( 4 ), 225 – 238 ( 2004 ).
   PubMedGoogle Scholar
• Kirchheiner J , KleinC , MeinekeIet al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 . Pharmacogenetics13 ( 10 ), 619 – 626 ( 2003 ).
   PubMedGoogle Scholar
• David SP , BrownRA , PapandonatosGDet al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation . Nicotine Tob. Res.9 ( 8 ), 821 – 833 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , BrosenK , DahlMLet al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages . Acta Psychiatr. Scand.104 ( 3 ), 173 – 192 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• PharmGKB . www.pharmgkb.org .
   Google Scholar
• Callen DF , BakerE , SimmersRN , SeshadriR , RoninsonIB . Localization of the human multiple drug resistance gene, MDR1, to 7q21.1 . Hum. Genet.77 ( 2 ), 142 – 144 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Ambudkar SV , DeyS , HrycynaCA , RamachandraM , PastanI , GottesmanMM . Biochemical, cellular, and pharmacological aspects of the multidrug transporter . Annu. Rev. Pharmacol. Toxicol.39 , 361 – 398 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Schinkel AH , JonkerJW . Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview . Adv. Drug Deliv. Rev.55 ( 1 ), 3 – 29 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Schinkel AH , WagenaarE , MolCA , Van DeemterL . P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs . J. Clin. Invest.97 ( 11 ), 2517 – 2524 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO , Von RichterOet al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo . Proc. Natl Acad. Sci. USA97 ( 7 ), 3473 – 3478 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Letrent SP , PollackGM , BrouwerKR , BrouwerKL . Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat . Pharm. Res.15 ( 4 ), 599 – 605 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Hajj A , KhabbazL , LaplancheJL , Peoc’hK . Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg . Pharmacogenomics14 ( 5 ), 575 – 585 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rhodin A , GronbladhA , GinyaHet al. Combined analysis of circulating beta-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects . Mol. Brain6 , 8 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sadhasivam S , ChidambaranV . Pharmacogenomics of opioids and perioperative pain management . Pharmacogenomics13 ( 15 ), 1719 – 1740 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ross JR , RileyJ , TaegetmeyerABet al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects . Cancer112 ( 6 ), 1390 – 1403 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Uhr M , GrauerMT . abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice . J. Psychiatr. Res.37 ( 3 ), 179 – 185 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Uhr M , GrauerMT , HolsboerF . Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption . Biol. Psychiatry54 ( 8 ), 840 – 846 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ejsing TB , HasselstromJ , LinnetK . The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites . Drug Metabol. Drug Interact.21 ( 3–4 ), 139 – 162 ( 2006 ).
   PubMedGoogle Scholar
• Gex-Fabry M , EapCB , OnedaBet al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response . Ther. Drug Monit.30 ( 4 ), 474 – 482 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Nikisch G , EapCB , BaumannP . Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study . Pharmacol. Res.58 ( 5–6 ), 344 – 347 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lachman HM , MorrowB , ShprintzenRet al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome . Am. J. Med. Genet.67 ( 5 ), 468 – 472 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Zubieta JK , HeitzegMM , SmithYRet al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor . Science299 ( 5610 ), 1240 – 1243 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ahlers SJ , ElensLL , Van GulikLet al. The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery . Br. J. Clin. Pharmacol.75 ( 6 ), 1506 – 1515 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Diatchenko L , SladeGD , NackleyAGet al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition . Hum. Mol. Genet.14 ( 1 ), 135 – 143 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Desmeules J , PiguetV , BessonMet al. Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism . Health Psychol.31 ( 2 ), 242 – 249 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Desmeules J , ChabertJ , RebsamenMet al. Central pain sensitization, COMT Val158Met polymorphism, and emotional factors in fibromyalgia . J. Pain15 ( 2 ), 129 – 135 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rakvag TT , KlepstadP , BaarCet al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients . Pain116 ( 1–2 ), 73 – 78 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC , SheteS , RakvagTet al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene . Pain130 ( 1–2 ), 25 – 30 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Szegedi A , RujescuD , TadicAet al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression . Pharmacogenomics J.5 ( 1 ), 49 – 53 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Perlis RH , FijalB , AdamsDH , SuttonVK , TrivediMH , HoustonJP . Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder . Biol. Psychiatry65 ( 9 ), 785 – 791 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Benedetti F , DallaspeziaS , ColomboC , LorenziC , PirovanoA , SmeraldiE . Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine . Eur. Psychiatry25 ( 8 ), 476 – 478 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tzeng DS , ChienCC , LungFW , YangCY . MAOA gene polymorphisms and response to mirtazapine in major depression . Hum. Psychopharmacol.24 ( 4 ), 293 – 300 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cusin C , SerrettiA , ZanardiRet al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity . Int. J. Neuropsychopharmacol.5 ( 1 ), 27 – 35 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Muller DJ , SchulzeTG , MacciardiFet al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter . Pharmacopsychiatry35 ( 4 ), 157 – 158 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Niitsu T , FabbriC , BentiniF , SerrettiA . Pharmacogenetics in major depression: a comprehensive meta-analysis . Prog. Neuropsychopharmacol. Biol. Psychiatry45C , 183 – 194 ( 2013 ).
   Google Scholar
• Arias B , CatalanR , GastoC , GutierrezB , FananasL . 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study . J. Clin. Psychopharmacol.23 ( 6 ), 563 – 567 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Ito K , YoshidaK , SatoKet al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine . Psychiatry Res.111 ( 2–3 ), 235 – 239 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Popp J , LeuchtS , HeresS , SteimerW . Serotonin transporter polymorphisms and side effects in antidepressant therapy–a pilot study . Pharmacogenomics7 ( 2 ), 159 – 166 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Smits K , SmitsL , PeetersFet al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors . Int. Clin. Psychopharmacol.22 ( 3 ), 137 – 143 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Smits KM , SmitsLJ , SchoutenJS , StelmaFF , NelemansP , PrinsMH . Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review . Mol. Psychiatry9 ( 5 ), 433 – 441 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wilkie MJ , SmithG , DayRKet al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy . Pharmacogenomics J.9 ( 1 ), 61 – 70 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Baffa A , HohoffC , BauneBTet al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression . Neuropsychobiology62 ( 2 ), 121 – 131 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kim H , LimSW , KimSet al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression . JAMA296 ( 13 ), 1609 – 1618 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lemonde S , DuL , BakishD , HrdinaP , AlbertPR . Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response . Int. J. Neuropsychopharmacol.7 ( 4 ), 501 – 506 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Serretti A , ArtioliP , LorenziC , PirovanoA , TubazioV , ZanardiR . The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings . Int. J. Neuropsychopharmacol.7 ( 4 ), 453 – 460 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Sato K , YoshidaK , TakahashiHet al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder . Neuropsychobiology46 ( 3 ), 136 – 140 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Cusin C , SerrettiA , LattuadaEet al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders . J. Psychiatr. Res.35 ( 4 ), 217 – 223 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Persu A , CoscoyS , HouotAM , CorvolP , BarbryP , JeunemaitreX . Polymorphisms of the gamma subunit of the epithelial Na+ channel in essential hypertension . J. Hypertens.17 ( 5 ), 639 – 645 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Moulard B , BuresiC , MalafosseA . Study of the voltage-gated sodium channel beta 1 subunit gene (SCN1B) in the benign familial infantile convulsions syndrome (BFIC) . Hum. Mutat.16 ( 2 ), 139 – 142 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Nassar MA , LevatoA , StirlingLC , WoodJN . Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8 . Mol. Pain1 , 24 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Nassar MA , StirlingLC , ForlaniGet al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain . Proc. Natl Acad. Sci. USA101 ( 34 ), 12706 – 12711 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Drenth JP , Te MorscheRH , GuilletG , TaiebA , KirbyRL , JansenJB . SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels . J. Invest. Dermatol.124 ( 6 ), 1333 – 1338 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Fertleman CR , BakerMD , ParkerKAet al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes . Neuron52 ( 5 ), 767 – 774 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Cox JJ , ReimannF , NicholasAKet al. An SCN9A channelopathy causes congenital inability to experience pain . Nature444 ( 7121 ), 894 – 898 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Goldberg YP , MacFarlaneJ , MacdonaldMLet al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations . Clin. Genet.71 ( 4 ), 311 – 319 ( 2007 ).
   PubMed Web of Science ®Google Scholar